Bibliographie : Cannabinoïdes et HIV/SIDA

Dr Christian Sueur, GRECC, août 2018.

  1. ABRAMS D.I., HILTON J.F., LEISER R.J. et al. : Short-term effects of cannabinoids in patients with HIV-1 infection : a randomized, placebo-controlled clinical trial, Annals of Internal Medicine, 2003, 139, 258-266.
  2. ABRAMS D.I., JAY C.A. et al : Cannabis in painful HIV-associated sensory neuropathy : a randomized placebo-controlled trial, Neurology, 2007, 68, 7, 515-521.
  3. ABRAMS D.I., COUEY P., SHADE S.B. et al. : Cannabinoid-Opioid Interaction in Chronic Pain, Clinical Pharmacology and Therapeutics, 2011, DOI : 10.1038/clpt.2011.188.
  4. AVRAHAM H.K. et al. : Impaired Neurogenesis by HIV-1-GP120 is rescued by genetic deletion of Fatty Acid Amide Hydrolase Enzyme, British Journal of Pharmacology, 2014.
  5. BEAL J.E., OLSON R., LAUBENSTEIN L. et al. : Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS, Journal of Pain and Symptom Management, 1995, 10, 2, 89-97.
  6. BEAL J.E., OLSON R., LEFKOWITZ, LAUBENSTEIN L. et al. : Long-term efficacy and safety of Dronabinol for acquired immunodeficiency syndrome-associated anorexia, Journal of Pain and Symptom Management, 1997, 14, 1, 7-14.
  7. BEDI G, FOLTIN R.W., GUNDERSON E.W. et al. : Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers : a controlled laboratory study, Psychopharmacology (Berl), 2010, 212, 4, 675-686.
  8. BELLE-ISLE , HATHAWAY : Barriers to access to medical marijuana for Canadians living with HIV/AIDS, AIDS Care, 2007, 19, 500-506.
  9. BRAITSTEIN et al. : Mary-Jane and her patients : sociodemographic and clinical characteristics of HIV-positive individuals using medical cannabis and antiretroviral agents, AIDES, 2001, 12, 532-533.
  10. CABRAL G.A. : Drugs of abuse, immune modulation, and AIDS, Journal of Neuroimmune Pharmacology, 2006, 1, 280-295.
  11. CHAO et al. : Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men, Drug and Alcohol Dependence, 2008, 94, 165, 171.
  12. CORLESS I.B., LINDGREN T., HOLZEMER W., ROBINSON L. et al. : Marijuana Effectiveness as an HIV Self-Care Strategy, Clinical Nurse Research, 2009, 18, 2, 172-193.
  13. COSTANTINO C.M., GUPTA A., YEWDALL A.W. et al. : Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells, PLoS One, 2012, 7, 3, e33961, 1-11.
  14. DEJESUS E., RODWICK B.M. et al. : Use of dronabinol improves appetite and reverses weight loss in HIV/AIDES-infected patients, J Int Assoc Physicians AIDS Care, 2007, 6, 2, 95-100.
  15. De JONG et al. : Marijuana usez and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea, Journal of Acquired Immune Deficiency Syndromes, 2005, 38, 43-46.
  16. D’SOUZA et al. : Medicinal and recreational marijuana use among HIV-infected women in the Women’s interagency HIV Cohort (WHIS), 1994-2010, Journal of Acquired Immune Deficiency Syndromes, 2012, 61, 618-626.
  17. ELLIS R.J. et al. : Smoked medicinal cannabis for neuropathic pain in HIV : a randomized, crossover clinical trial, Neuropsychopharmacology, 2008, 34, 672-680.
  18. FOGARTY A., RAWSTORNE P. et al. : Marijuana as therapy for people living with HIV/AIDS : social and health aspects, AIDS Care, 2007, 19, 2, 295-301.
  19. FURLER M.D., EINARSON T.R., MILLSON M., WALMSLEY S., BENDAYAN R. : Medicinal and recreational marijuana use by patients infected with HIV, Aids Patient Care and STDs, 2004, 18, 215-228.
  20. GORTER R., SEEFRIED M., VOLBERDING P. : Dronabinol effects on weight in patients with HIV infection, AIDS, 1992, 6, 1, 127.
  21. GORTER R. : Management of anorexia-cachexia associated with cancer and HIV

Infection, Oncology (Huntingt), 1995, 5, 13-17.

  1. GROTENHERMEN F. : Cannabis en Médecine. Un guide pratique des applications médicales du Cannabis et du THC, Editions Indica (Version numérique), 2009, « Sida » p. 107.
  2. GROTENHERMEN F. : Chanvre en Médecine. Redécouverte d’une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « VIH/sida », p 132.
  3. GROTENHERMEN F. : Chanvre en Médecine. Redécouverte d’une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « Effet antiviral sur le VIH », 158.
  4. GURWITZ D., KLOOG Y. : Do endogenous cannabinoids contribute to HIV-mediated immune failure?, Mol Med Today 1998, 4, 196-200.
  5. HANEY M. : Effects of smocked marijuana in healthy and HIV+marijuana smokers, Journal of Clinical Pharmacology, 2002, 42, S1, 34S-40S.
  6. HANEY M., RABKIN J. E., GUNDERSON, FOLTIN R.W. : Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood, Psychopharmacology (Berl), 2005, 181, 1, 170-178.

DOI : 10.1007/s00213-005-2242-2.

  1. HANEY M. : Dronabinol and Marijuana in HIV-Positive Marijuana Smokers : Caloric Intake, Mood and Sleep, Journal of Acquired Immune Deficiency Syndromes, 2007, 45, 5, 545-554. DOI : 10.1097/QAI.0b013e31811ed205 .
  2. HU S., SHENG W.S., ROCK R.B. : Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis, Journal of Neuroimmune Pharmacology, 2011, 6, 528-539.
  3. JAMES J. S. : Marijuana safety study completed : weight gain, no safety problems, AIDS Treat News, 2000, 3-4.
  4. KASLOW R.A., BLACKWELDER W.C., OSTROW D.G., YERGD., PALENICEK J., COULSON A.H., VALDISERRI R.O. : No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals, JAMA Journal of the American Medical Association, 1989, 261, 3424-3429.
  5. KEEN L., ABBATE A., BLANDEN G. et al. : Confirmed marijuana use and lymphocyte count in black people living with HIV, Drug and Alcohol Dependence, 2017, 180, 22-25.
  6. KIM H.J., SHIN A.H., THAYER S.A. : Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss, Molecular Pharmacology, 2011, 80, 357-366.
  7. KOSEL B.W et al. : The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir, AIDS, 2002, 16, 543-550.
  8. LISTED N. : Nausea and vomiting associated with HIV therapy are reduced with Marinol, AIDS Read, 2000, 10, 701-702.
  9. LU T.S. et al. : Cannabinoids inhibit HIV-1 gp120-mediated insults içn brain microvascular endothelial cells, Journal of Immunology, 2008, 181, 6406-6416.
  10. LUTGE E.E., GRAY A., SIEGFRIED: The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS, Cochrane Database Systematic Review, 2013 Apr 30, 4, CD005175.
  11. MARCELLIN F., LIONS C., ROSENTHAL E., CARRIERI M.P. et al. : No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort), Drug and Alcohol Review, 2016, 36, 2.
  12. MERLIN J.S., BULLS H.W., VUCOVICH L.A., EDELMAN E.J., STARRELS J.L. : Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV : a systematic review, AIDS Care, 2016, 28, 12.

DOI : 10.1080/09540121.2016.1191612

  1. MOLINA P.E. et al. : Cannabinoid administration attenuates the progression of simian immunodeficiency virus, AIDS Research and Human Retroviruses, 2011, 27, 585-592.
  2. MOLINA P.E. et al. : Cannabinoid Neuroimmune Modulation of SIV Disease, Journal of Neuroimmune Pharmacology, 2011.
  3. MOLINA P.E. et al. : Modulation of Gut-Specific Mechanisms by Chronic Delta-Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus : A Systems Biology Analysis, AIDS Research and Human Retroviruses, 2014.
  4. PLASSE T.F., GORTER R.W., KRASNOV S.H. et al. : Recent clinical experience with dronabinol, Pharmacotherapy, Biochemistry and Behavior, 1991, 40, 695-700.
  5. PLASSE T.F., CONANT M. et al. : Dronabinol stimulates appetite and causes weight gain in HIV patient, International Conférence on AIDS, 1992, 8, 3, 122.
  6. PRENTISS D., POWER R., BALMAS G., TZUANG G., ISRAELSKI D.M. : Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting, Journal Acquir Immune Defic Syndrom, 2004, 35, 38-45.
  7. PUROHIT V., RAPAKA R.S., RUTTER J. : Cannabinoid Receptor-2 and HIV-Associated Neurocognitive Disorders, Journal of Neuroimmune Pharmacology, 2014, 9, 4, 447-453.
  8. RAMIREZ S.H., REICHENBACH N.L., FAN S., ROM S. et al. : Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists, Journal of Leukocyte Biology, 2013, 93, DOI 10.1189/jlb.1012523.
  9. RIGGS P.K., VAIDA F., ROSSI S.S. et al. : A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men, Brain Research, 2012, 1431, 46-52.
  10. RUSSO E. et al. : Cannabis Therapeutics in HIV/AIDS, Journal of Cannabis Therapeutics, 2002, Vol 1, ¾.
  11. SCHRIER R. : Effects of medicinal marijuana on CD4 immunity in AIDS, University of San Diego Health Sciences, Center for Medical Cannabis Research, Report to the Legislature and Governor of the State of California presenting findings pursuant to SB 847 which created the CMCR and provided state funding,
  12. SIDNEY S. : Marijuana use in HIV-positive and AIDS patients : Results of an anonymous mail survey, Journal of Cannabis Therapeutics, 2001, 1, 3-4, 35-43.
  13. SOHLER N.L. et al.: Cannabis use is associated with Lower Odds of Prescription Opioid Analgésic Use among HIV-Infected Individuals With Chronic Pain, Substances Use and Misuses, 2018 Jan 17, 1-6.
  14. STEFANO G.B., SALZET, M., BILFINGER T.V. : Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release, J Cardiovasc Pharmacol, 1998, 31, 862- 868.
  15. STRUWE M. et al. : Effect of dronabinol on nutritional status in HIV infection, Annals of Pharmacotherapy, 1993, 27, 827-831.
  16. TAHAMTAN A., TAVAKOLI-YARAKI M., RYGIEL T.P., et al. : Effects of cannabinoids and their receptors on viral infection, Journal of Medical Virology, 2015, DOI 10.1002/jmv.
  17. Temple University Health System : Temple scientists weaken human immunodeficiency virus – HIV infection in immune cells using synthetic agents, 2013.
  18. THAMES A.D., MAHMOOD Z., BURGGREN A .C et al. : Combined effects of HIV and marijuana use on neurocognitive functionning and immune status, AIDS Care, 2016, 28, 5.
  19. TIMPONE J.G. et al. : The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome, The DATRI 004 Study Group, Division of AIDS Treatment Research Initiative, AIDS Research and Human Retroviruses, 1997, 13, 305-315.
  20. WARE M.A. et al. : Cannabis consumption by persons living with HIV/AIDES : patterns and prevalence of use, Journal of Cannabis Therapeutics, 2003, 3, 3-15.
  21. WARE M.A., WANG T., SHAPIRO S. et al. : Smoked cannabis for chronic neuropathic pain : a randomized controlled trial, Research – Canadian Medical Association Journal, 2010, 182, (14), 694-701.
  22. WINSAUER P.J. et al. : Tolerance to chronic delta-9-tetrahydrocannabinol (delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus, Experimental Clinical Pharmacology, 2011, 19, 154-172.
  23. WOOLRIDGE et al. : Cannabis use in HIV for pain and other medical symptoms, Journal of Pain Symptom Management, 2005, 29, 358-367.

 

 

 

Pièces jointes

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *